Clinical Trial Update: SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC

View source ↗

Summary

A study evaluating SIRT or TACE in combination with lenvatinib and a PD-1/PD-L1 inhibitor for unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1/PD-L1 inhibitor (unspecified)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Status: COMPLETED